Nippon Shinyaku Co., Ltd. (4516.T) JPX

Currency In JPY

AD

Nippon Shinyaku Co., Ltd.

Address

14, Nishinosho-Monguchi-cho

Kyoto, 601-8550

Japan

Phone

81 7 5321 1111

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Employees

2213

First IPO Date

January 01, 2001

Key Executives

NameTitlePayYear Born
Katsumi NodaCorporate Officer & Department Manager of Tokyo Business Office0N/A
Keiichi KuwanoGM of Research & Development and Director01967
Mitsuharu KoizumiHead of Dir., Pers., Gen. Affairs, Risk Man.,Comp. & Dig. Trans. Dept. (Pers. & DX) and Corp. Off.0N/A
Hideyuki FujiiAccounting & Finance Department Manager0N/A
Hitoshi IshizawaGM of Functional Food Division & Director01961
Toru YamaguchiCorporate Officer & Department Manager of Odawara Central Factory0N/A
Toru NakaiPresident & Director01971
Kazuyuki YamateCorporate Officer & Head of Digital Transformation Div.0N/A
Manabu BeppuCorporate Officer and Head of R & D Planning and Administration Div.0N/A
Yoko NakanishiCorporate Officer & Department Manager of Human Resources Dept.0N/A
Takashi TakayaGM of Personnel, General Affairs, Risk Mgmt, Compliance & Digital Trans and Director01960
Hitomi KimuraDirector of Resource Procurement, Production & Assurance & Director01961
Yoshizumi TanakaHead of Regulatory Affairs Supervision & Assurance Division and Corporate Officer0N/A
Kazuyuki IwataDirector of Sales and Marketing & Director01966
Hayato WadaCorporate Officer & Department Manager of Kansai Business Office0N/A
Takanori EdamitsuHead of Business Management & Sustainability and Director01963
Masaya TodaHead of Licensing & Alliance Division and Corporate Officer0N/A
AD

Description

Nippon Shinyaku Co., Ltd., an enterprise established in Kyoto, Japan, in 1911, engages globally in the production and distribution of pharmaceutical products and functional foods. Its reach extends across Japan, Switzerland, and various international markets, with operations structured into two core divisions: Pharmaceuticals and Functional Food. The Pharmaceutical division concentrates on a wide array of therapeutic areas, encompassing conditions affecting the urinary system, inflammatory and allergic responses, hematologic malignancies, cardiovascular and metabolic disorders, gastrointestinal issues, and other diverse diseases. Its extensive product catalog features notable treatments such as Zalutia, designed for urinary difficulties arising from benign prostatic hypertrophy; Eviprostat, also for prostatic hypertrophy; Bladderon for frequent urination; and Estracyt, targeting prostate cancer. For erectile dysfunction, it provides Cialis. In hematology and oncology, the company's portfolio includes Vidaza for myelodysplastic syndrome; Cylocide and CylocideN for solid tumors, acute leukemia, and malignant lymphoma; Gazyva, a humanized anti-CD20 monoclonal antibody; Defiterio for sinusoidal obstruction syndrome; and Trisenox and Amnolake for relapsed and refractory acute promyelocytic leukemia. Nippon Shinyaku also offers Uptravi, Adcirca, and Opsumit for the management of pulmonary arterial hypertension, alongside VILTEPSO for muscular dystrophy. Other specialized medications include Lunabel LD and Lunabel ULD for dysmenorrhea; Erizas, a dry powder inhaler for allergic rhinitis; Azunol Gargle liquid, an azulene-based gargling solution; Isobide for oral osmotic diuresis and Meniere's disease; Cephadol for vertigo; Livostin for allergic rhinitis and conjunctivitis; Regtect, aimed at maintaining alcohol abstinence; and Onetram and Tramal for the treatment of cancer and chronic pain. Furthermore, the company actively conducts research, development, and marketing efforts in the fields of gynecology, otorhinolaryngology, and orthopedics. The Functional Food segment broadens the company's offerings, supplying various health-focused ingredients, food preservatives, protein preparations, dietary supplements, and a selection of spices and condiments.

AD